25 citations
,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” In this analysis, safety data from two clinical trials showed that baricitinib for severe alopecia areata had predictable side effects like infections and elevated CPK, with some serious adverse events noted at low incidence rates; no deaths were reported.
April 2016 in “Journal of The American Academy of Dermatology” Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.
December 2022 in “Journal of The European Academy of Dermatology and Venereology” This corrigendum clarifies that withdrawal rates due to treatment-related side effects were misstated in a study on topical finasteride for male androgenetic alopecia; higher withdrawal rates were associated with oral finasteride, not topical.
February 2024 in “Journal of the European Academy of Dermatology and Venereology” In this study, baricitinib for severe alopecia areata showed sustained efficacy over 104 weeks, with most Week-52 responders maintaining significant hair regrowth and some mixed responders improving further with long-term treatment.
May 2019 in “Journal of clinical oncology” This Phase 1 study reported that topical application of BPM31543 was safe and well-tolerated in patients receiving taxane-based chemotherapy, with some experiencing less than 50% hair loss, suggesting potential efficacy in reducing chemotherapy-induced alopecia, although no maximum tolerated dose was identified.